After finishing at $1.39 in the prior trading day, Akebia Therapeutics Inc. (NASDAQ: AKBA) closed at $1.35, down -2.88%. In other words, the price has decreased by -$0.0400 from its previous closing price. On the day, 3039679 shares were traded. AKBA stock price reached its highest trading level at $1.4000 during the session, while it also had its lowest trading level at $1.3200.
Ratios:
Our goal is to gain a better understanding of AKBA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.14 and its Current Ratio is at 1.38.
On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.
Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 01 when Butler John P. sold 46,489 shares for $1.68 per share. The transaction valued at 78,102 led to the insider holds 2,128,883 shares of the business.
Burke Steven Keith sold 24,311 shares of AKBA for $40,842 on Feb 01. The SVP, Chief Medical Officer now owns 711,376 shares after completing the transaction at $1.68 per share. On May 25, another insider, Dahan Michel, who serves as the SVP, Chief Operating Officer of the company, sold 95,478 shares for $1.22 each. As a result, the insider received 116,760 and left with 574,037 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 254.33M and an Enterprise Value of 265.50M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.31. Its current Enterprise Value per Revenue stands at 1.37 whereas that against EBITDA is 415.49.
Stock Price History:
Over the past 52 weeks, AKBA has reached a high of $1.84, while it has fallen to a 52-week low of $0.49. The 50-Day Moving Average of the stock is 1.4342, while the 200-Day Moving Average is calculated to be 1.2154.
Shares Statistics:
The stock has traded on average 1.74M shares per day over the past 3-months and 2.2M shares per day over the last 10 days, according to various share statistics. A total of 184.14M shares are outstanding, with a floating share count of 165.56M. Insiders hold about 12.12% of the company’s shares, while institutions hold 20.45% stake in the company. Shares short for AKBA as of Jan 31, 2024 were 8.78M with a Short Ratio of 5.05, compared to 7.87M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 4.66% and a Short% of Float of 4.72%.
Earnings Estimates
Its stock is currently analyzed by 3 different market analysts. On average, analysts expect EPS of -$0.04 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.06, while EPS last year was -$0.04. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.08 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.3 and -$0.34 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.28, with 3 analysts recommending between -$0.25 and -$0.32.
Revenue Estimates
3 analysts predict $55.39M in revenue for the current quarter. It ranges from a high estimate of $56.31M to a low estimate of $54.9M. As of the current estimate, Akebia Therapeutics Inc.’s year-ago sales were $55.18M, an estimated increase of 0.40% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $41.61M, an increase of 3.70% over than the figure of $0.40% in the same quarter last year. There is a high estimate of $43.1M for the next quarter, whereas the lowest estimate is $38.8M.
A total of 3 analysts have provided revenue estimates for AKBA’s current fiscal year. The highest revenue estimate was $194.74M, while the lowest revenue estimate was $193.39M, resulting in an average revenue estimate of $193.88M. In the same quarter a year ago, actual revenue was $292.6M, down -33.70% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $192.65M in the next fiscal year. The high estimate is $194.94M and the low estimate is $188.11M. The average revenue growth estimate for next year is down -0.60% from the average revenue estimate for this year.
